---
title: "Jeito II S.L.P. Discloses Investment in Odyssey Therapeutics with 7.8% Stake"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286603354.md"
description: "Jeito II S.L.P., a French investment fund, has acquired a 7.8% stake in Odyssey Therapeutics, Inc., purchasing 1,388,888 shares at $18 during the company's IPO. This investment allows Jeito to exert significant influence, with an executive already on Odyssey's board. Jeito plans to review its position and may adjust its holdings while maintaining an active dialogue with Odyssey's management."
datetime: "2026-05-15T19:06:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286603354.md)
  - [en](https://longbridge.com/en/news/286603354.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286603354.md)
---

# Jeito II S.L.P. Discloses Investment in Odyssey Therapeutics with 7.8% Stake

Jeito II S.L.P., a French investment fund, disclosed a 7.8% stake in Odyssey Therapeutics, Inc. The position reflects conversions tied to Odyssey’s May 11, 2026 IPO and a purchase of 1,388,888 shares at $18 in the offering. The move gives Jeito meaningful influence alongside an existing Jeito executive who already serves on Odyssey’s board.

**Investor Intent**

Jeito II S.L.P. says it holds the shares for investment and will keep reviewing the position. The fund may buy more or sell shares over time as it evaluates Odyssey.

Jeito points to an active dialogue with the company. “Ksenija Pavletic, who is the General Partner and Chief Commercial Officer at Jeito Capital SAS, is a director of the Issuer,” and the group “may engage in discussions from time to time with the Board, the Issuer’s management or the Issuer’s other stockholders.”

**Investor's Background**

Jeito II S.L.P. is a French limited partnership and private investment fund focused on healthcare. Its manager, Jeito Capital SAS, is a Paris-based life sciences venture capital firm founded by Dr. Rafaèle Tordjman. Jeito typically backs clinical-stage and commercial-ready biotech companies in Europe and the U.S., aiming to scale innovative therapies.

Original SEC Filing: Odyssey Therapeutics, Inc. \[ ODTX \] - SCHEDULE 13D - May. 15, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [ODTX.US](https://longbridge.com/en/quote/ODTX.US.md)

## Related News & Research

- [These 3 engineering roles are now converging, says EY's AI leader](https://longbridge.com/en/news/286538922.md)
- [Stifel Nicolaus Keeps Their Buy Rating on Nurix Therapeutics (NRIX)](https://longbridge.com/en/news/286587770.md)
- [Pelthos Therapeutics GAAP EPS of -$3.09, revenue of $10.7M](https://longbridge.com/en/news/286430906.md)
- [Berto Acquisition Corp. II Announces Pricing of Upsized $274,000,000 Initial Public Offering | GUAC Stock News](https://longbridge.com/en/news/286500639.md)
- [Zodiac Partners II, Llc Launches A $46 Million Tender Offer To Acquire Destination Xl Group, Inc. For $0.82 Per Share In Cash](https://longbridge.com/en/news/286112972.md)